Krystal Biotech registers early-phase trial of KB111 gene therapy for Hailey-Hailey Disease
A new open-label study will test topical KB111 in up to 7 patients with Hailey-Hailey Disease over a 12-week treatment period.
Krystal Biotech's sole registry update this week covers a newly listed early phase study of its gene therapy candidate KB111.
- KB111, an early phase1, open-label trial known as HALITE-1, is recruiting patients with Hailey-Hailey Disease. The study plans to enroll up to 7 subjects who will receive topical KB111 to treat HHD lesions for 12 weeks.1 The therapy itself is described as a non-integrating, HSV-1 based vector carrying a full-length human ATP2C1 gene, delivered in gel form for topical use, as detailed in the study record. Krystal Biotech is the lead sponsor, and the single site listed is in Miami, Florida.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.